within Pharmacolibrary.Drugs.ATC.J;

model J01XX08_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 7.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,
    adminCount     = 1,
    Vd             = 0.022699999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Linezolid is a synthetic antibiotic of the oxazolidinone class. It is primarily used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Linezolid is approved for clinical use and commonly prescribed for pneumonia, skin and soft tissue infections, and other severe bacterial infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers aged 18-55 years after single IV 600 mg dose, both sexes.</p><h4>References</h4><ol><li><p>Heidari, S, &amp; Khalili, H (2023). Linezolid pharmacokinetics: a systematic review for the best clinical practice. <i>European journal of clinical pharmacology</i> 79(2) 195–206. DOI:<a href=&quot;https://doi.org/10.1007/s00228-022-03446-4&quot;>10.1007/s00228-022-03446-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36565357/&quot;>https://pubmed.ncbi.nlm.nih.gov/36565357</a></p></li><li><p>Thibault, C, et al., &amp; Autmizguine, J (2019). Population Pharmacokinetics of Intravenous Linezolid in Premature Infants. <i>The Pediatric infectious disease journal</i> 38(1) 82–88. DOI:<a href=&quot;https://doi.org/10.1097/INF.0000000000002067&quot;>10.1097/INF.0000000000002067</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29634620/&quot;>https://pubmed.ncbi.nlm.nih.gov/29634620</a></p></li><li><p>Sicard, M, et al., &amp; Guen, CG (2015). Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. <i>European journal of clinical pharmacology</i> 71(5) 611–615. DOI:<a href=&quot;https://doi.org/10.1007/s00228-015-1813-3&quot;>10.1007/s00228-015-1813-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25740677/&quot;>https://pubmed.ncbi.nlm.nih.gov/25740677</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01XX08_1;
